The Marburgvirus Infections (Marburg Hemorrhagic Fever) drugs in development market research report provides comprehensive information on the therapeutics under development for Marburgvirus Infections (Marburg Hemorrhagic Fever), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Marburgvirus Infections (Marburg Hemorrhagic Fever). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Marburgvirus Infections (Marburg Hemorrhagic Fever) and features dormant and discontinued products.

GlobalData tracks 44 drugs in development for Marburgvirus Infections (Marburg Hemorrhagic Fever) by 36 companies/universities/institutes. The top development phase for Marburgvirus Infections (Marburg Hemorrhagic Fever) is preclinical with 31 drugs in that stage. The Marburgvirus Infections (Marburg Hemorrhagic Fever) pipeline has 35 drugs in development by companies and nine by universities/ institutes. Some of the companies in the Marburgvirus Infections (Marburg Hemorrhagic Fever) pipeline products market are: Integrated BioTherapeutics, GeoVax Labs and Dominari.

The key targets in the Marburgvirus Infections (Marburg Hemorrhagic Fever) pipeline products market include Ebola virus Matrix Protein VP40 (Membrane Associated Protein VP40 or VP40), Glycoprotein, and Hepatitis A Virus Cellular Receptor 1 (Kidney Injury Molecule 1 or T Cell Immunoglobulin And Mucin Domain Containing Protein 1 or T-Cell Immunoglobulin Mucin Receptor 1 or T Cell Membrane Protein 1 or CD365 or HAVCR1).

The key mechanisms of action in the Marburgvirus Infections (Marburg Hemorrhagic Fever) pipeline product include Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) Inhibitor with one drug in Preclinical. The Marburgvirus Infections (Marburg Hemorrhagic Fever) pipeline products include six routes of administration with the top ROA being Intramuscular and ten key molecule types in the Marburgvirus Infections (Marburg Hemorrhagic Fever) pipeline products market including Small Molecule, and Subunit Vaccine.

Marburgvirus Infections (Marburg Hemorrhagic Fever) overview

Marburg hemorrhagic fever is a rare, acute infectious disease that affects both human and nonhuman primates. Symptoms include fever, headache, chills, weakness, diarrhea, stomach pain, and weight loss.

For a complete picture of Marburgvirus Infections (Marburg Hemorrhagic Fever)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.